申请人:AstraZeneca AB
公开号:US06716831B1
公开(公告)日:2004-04-06
A pyrimidine derivative of formula (I) or (I′): wherein: Rx is a substituent as defined within; Q1 is optionally substituted phenyl, and Q1 bears a substituent of formula (Ia) wherein: X, Y1, Y2, Z, n, and m are as defined within; —NQ2 is an optionally substituted heterocyclic moiety containing one hydrogen heteroatom and optionally containing a further heteroatom; or a pharmaceutically acceptable salt in vivo hydrolysable ester thereof; are useful as anti-cancer agents. Processes for their manufacture and pharmaceutical compositions containing them are described.
公式(I)或(I')的嘧啶衍生物:其中:Rx是定义内的取代基;Q1是可选取代的苯基,并且Q1带有式(Ia)的取代基,其中:X,Y1,Y2,Z,n和m如定义内;—NQ2是可选取代的杂环基,含有一个氢杂原子,且可选含有另一个杂原子;或其体内可水解酯的药学上可接受的盐;可用作抗癌剂。描述了其制造过程和含有它们的制药组合物。